GoldenGolden
Advanced Search
CareDx

CareDx

CareDx is a Brisbane, California-based manufacturer of molecular diagnostics technologies.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

May 14, 2020
CareDx and Veracyte announce exclusive partnership for transplant rejection testing on nCounter System.

September 2019
CareDx announces plans to develop HistoMap, a gene expression profiling solution to identify allograft rejection in transplant biopsy tissue.
August 5, 2009
CareDx raises a $14,400,000 series G round from Bristol-Myers Squibb, Burrill & Company, DAG Ventures, Integral Capital Partners, Intel Capital, Kleiner Perkins Caufield & Byers, New Leaf Venture Partners, Sprout Group and TPG Growth.

Funding rounds

Patents

Products

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 30, 2021
BioSpace
CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces that Hannah Valantine, MD has joined CareDx's Board of Directors.
American Association of Kidney Patients
June 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- The American Association of Kidney Patients (AAKP) recently hosted its 4th Annual Public Policy Summit entitled Patient Voice & Patient Choice:...
BioSpace
June 9, 2021
BioSpace
CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, congratulates Hannah Valantine, MD on her State of the Art Lecture at the 2021 American Transplant Congress about the importance of equity in transplantation and genomic solutions to improve inclusivity.
BioSpace
April 22, 2021
BioSpace
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today that Palmetto MolDx finalized the local coverage determination "Molecular Testing for Solid Organ Allograft Rejection," reaffirming coverage and patient access to transplant testing service
BioSpace
April 8, 2021
BioSpace
CareDx, Inc. announced that they have launched a fully-functional next generation sequencing HLA typing service lab in Stockholm, Sweden to support companies in research and academic studies working on HLA applications in vaccine and drug development as well as disease association studies.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.